Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 1.00 |
| ▸ | FNTB | P49356 | 17/20 | 1.00 |
| ▸ | PGGT1B | P53609 | 14/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.84 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16136644 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1BCL2L1 | |
| SCHEMBL16499927 | 1.00 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL28675162 | 0.95 | FNTA (0.91) | FNTAFNTBPGGT1BTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL31146895 | 0.95 | FNTA (0.91) | FNTAFNTBPGGT1BTDP1BCL2L1 | |
| Trifluoroacetic Acid SCHEMBL28675164 | 0.95 | FNTA (0.91) | FNTAFNTBPGGT1BTDP1BCL2L1 | |
| SCHEMBL14169141 | 0.93 | FNTA (0.87) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL29392871 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL16136630 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| SCHEMBL4283635 | 0.91 | FNTA (1.00) | FNTAFNTBPGGT1BTDP1 | |
| Trifluoroacetic Acid SCHEMBL16499780 | 0.88 | FNTA (0.89) | FNTAFNTBPGGT1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527781-B2 | Treatment of neurodegenerative conditions by disruption of Rhes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | claimed |
| WO-2024194402-A1 | FARNESYL TRANSFERASE INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | claimed |
| CN-117940155-A | Immunogenic composition, preparation method and application thereof | 清华大学 | 2024-04-26 | — | — | CN | claimed |
| WO-2023036249-A1 | IMMUNOGENIC COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 清华大学 | 2023-03-16 | — | — | WO | claimed |
| US-12527781-B2 | Treatment of neurodegenerative conditions by disruption of Rhes | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4604958-A1 | METHOD OF TREATING ADULT-ONSET AUTOSOMAL DOMINANT LEUKODYSTROPHY (ADLD) | Agency for Science, Technology and Research (SG) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025101692-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR ANOMALIES | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2025-05-15 | — | — | WO | disclosed |
| WO-2024194402-A1 | FARNESYL TRANSFERASE INHIBITOR FOR USE IN METHODS FOR THE TREATMENT OF HRD CANCER | INSTITUT CURIE (FR) | 2024-09-26 | — | — | WO | disclosed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| CN-117940155-A | Immunogenic composition, preparation method and application thereof | 清华大学 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024085805-A1 | METHOD OF TREATING ADULT-ONSET AUTOSOMAL DOMINANT LEUKODYSTROPHY (ADLD) | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2024-04-25 | — | — | WO | disclosed |
| US-20230398146-A1 | IMMUNE MODULATION OF MYELOID DERIVED SUPPRESSIVE CELL FUNCTION FOR CANCER TREATMENT | SURGE Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| WO-2014160729-A1 | COMPOSITION AND METHOD FOR TREATING CANCER | CELLWORKS RESEARCH INDIA PVT. LTD (IN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2011088126-A2 | TREATMENT OF VIRAL INFECTION WITH PRENYLTRANSFERASE INHIBITORS | EIGER BIOPHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110110891-A1 | Methods of Treating Hepatitis C Virus Infection | NIH-DEITR | 2011-05-12 | — | — | US | disclosed |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2009137111-A1 | METHODS OF TREATING HEPATITIS C VIRUS INFECTION | THE J. DAVID GLADSTONE INSTITUTES (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2008080110-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | ALCON, INC. (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153819-A1 | METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | ALCON MANUFACTURING, LTD. (US) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527781-B2 | Treatment of neurodegenerative conditions by disruption of Rhes | RHEB, FNTA, FNTB | FNTA 2/4885FNTB 3/4885PGGT1B 441/4885 |
| US-20070232675-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885FNTB 12/4885PGGT1B 8/4885 |
| US-20110110891-A1 | Methods of Treating Hepatitis C Virus Infection | HAVCR2, HCCS, HDGF | FNTA 2705/4885FNTB 1264/4885PGGT1B 4325/4885 |
| US-20100120851-A1 | PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA | FNTA, PTAR1, RHOA | FNTA 1/4885FNTB 12/4885PGGT1B 8/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | FNTA 3930/4885FNTB 2672/4885PGGT1B 1503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.